Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech News St. Vincent & Grenadines.
Press releases published on September 17, 2025
TerraMaster Lancia il NAS a Quattro Alloggiamenti F4-425: Inizia un Nuovo Capitolo nelle Prestazioni per l'Archiviazione Domestica con Intel x86
SHENZHEN, China, Sept. 17, 2025 (GLOBE NEWSWIRE) -- TerraMaster, leader globale nell'innovazione nel campo delle unità di archiviazione di rete (NAS), lancia il NAS a quattro alloggiamenti F4-425, progettato come un centro di intrattenimento e …
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis (PD), today announced the submission of its Clinical …
Oruka Therapeutics Announces $180 Million Private Placement
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, …
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 to begin in early 2026 SCOTCH PLAINS, N.J., Sept. 17, …
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo …
Communiqué de presse : EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée
EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée Dans l’étude de phase 2a, le brivekimig a entraîné des améliorations cliniquement significatives des critères d’ …
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable …
Dubai-Based PartyPlatform Reaches 10,000 Users, Disrupts UAE Event Planning Industry with Smarter Marketplace
Photo Courtesy of: PartyPlatform DUBAI, United Arab Emirates, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The PartyPlatform announced today that it has drawn 10,000 unique visitors, marking its rapid rise as the leading solution for organizing gatherings across the …
Aduro Clean Technologies Europe schließt sich niederländischer Handelsdelegation auf der Expo 2025 in Osaka, Japan, an
LONDON, Ontario, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc („Aduro” oder das „Unternehmen”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein Unternehmen für saubere Technologien, das die Kraft der Chemie nutzt, um minderwertige Rohstoffe wie …
Aduro Clean Technologies Europe se joint à la délégation commerciale néerlandaise à l’Exposition universelle de 2025 à Osaka, au Japon
LONDON, Ontario, 17 sept. 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (« Aduro » ou la « Société ») (Nasdaq : ADUR) (CSE : ACT) (FSE : 9D5), une entreprise du secteur des technologies propres qui exploite le potentiel de la chimie pour …